Kimia Biosciences Ltd

The 50-day moving average has crossed above the 200-day moving average for Kimia Biosciences Ltd, signalling a golden cross on 2 Jun 2026. Yet, the stock declined 1.35% on the same day, while monthly technical indicators remain bearish. This juxtaposition of signals calls for a detailed examination of the cross’s reliability.

Kimia Biosciences Ltd., a micro-cap pharmaceutical company specialising in bulk drug manufacturing, reported a dramatic 81.41% quarter-on-quarter decline in net profit for Q4 FY26, posting ₹0.37 crores compared to ₹1.99 crores in Q4 FY25. The sharp earnings contraction occurred despite relatively stable revenue performance, with net sales declining 28.87% year-on-year to ₹27.20 crores. The stock, currently trading at ₹36.50 with a market capitalisation of ₹168.00 crores, has struggled over the past year, delivering negative returns of 27.01% whilst the broader pharmaceuticals sector gained 9.25%.

Kimia Biosciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 09 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 24 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Kimia Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Kimia Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 May 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Kimia Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Kimia Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 9 April 2026, driven primarily by improvements in its technical outlook despite ongoing fundamental challenges. This shift reflects a nuanced reassessment across quality, valuation, financial trends, and technical indicators, signalling a cautious but more optimistic stance on the micro-cap pharmaceutical company.

Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 April 2026, providing investors with the latest insights into the company’s performance and outlook.

A sharp decline over the past three sessions has dragged Kimia Biosciences Ltd to a fresh 52-week low of Rs 23.2 on 30 Mar 2026, marking a 12.77% loss in that period and extending its underperformance well beyond the broader market's modest retreat.

A sharp decline in Kimia Biosciences Ltd has pushed the stock to a fresh 52-week low of Rs 24 on 27 Mar 2026, marking a significant 44.19% drop over the past year and a 16.29% fall in just the last two sessions. This downturn comes amid a broader market sell-off, but the stock’s underperformance far exceeds sector and benchmark indices, raising questions about the underlying factors driving this weakness.

Kimia Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 23 March 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s overall outlook remains bleak due to high debt levels, poor long-term growth, and underperformance relative to the broader market.

Kimia Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 10 March 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The company’s Mojo Score improved to 34.0, reflecting a modestly less negative outlook, while the Mojo Grade moved from Strong Sell to Sell. This article analyses the four key parameters influencing this rating change: Quality, Valuation, Financial Trend, and Technicals.

Kimia Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 2 March 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s long-term growth prospects remain subdued, compounded by high leverage and underperformance relative to the broader market.

Kimia Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Kimia Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 February 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 19 February 2026, providing investors with the latest insights into the company’s performance and outlook.